Teladoc Inc (NYSE:TDOC) was the target of some unusual options trading activity on Tuesday. Investors purchased 6,996 call options on the stock. This is an increase of approximately 1,082% compared to the average volume of 592 call options.
In related news, insider Adam C. Vandervoort sold 24,250 shares of the company’s stock in a transaction that occurred on Monday, July 9th. The shares were sold at an average price of $64.28, for a total transaction of $1,558,790.00. Following the completion of the transaction, the insider now owns 12,272 shares of the company’s stock, valued at $788,844.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jason N. Gorevic sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $66.11, for a total transaction of $1,652,750.00. Following the transaction, the chief executive officer now directly owns 586,184 shares of the company’s stock, valued at approximately $38,752,624.24. The disclosure for this sale can be found here. Insiders have sold 286,781 shares of company stock worth $19,429,607 in the last three months. Insiders own 3.95% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. We Are One Seven LLC increased its position in shares of Teladoc by 241.1% in the first quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock worth $115,000 after acquiring an additional 2,011 shares in the last quarter. Garner Asset Management Corp acquired a new stake in Teladoc during the 2nd quarter valued at $200,000. Pier 88 Investment Partners LLC acquired a new stake in Teladoc during the 2nd quarter valued at $201,000. Aperio Group LLC acquired a new stake in Teladoc during the 2nd quarter valued at $201,000. Finally, California Public Employees Retirement System acquired a new stake in Teladoc during the 2nd quarter valued at $203,000.
Several brokerages recently commented on TDOC. SunTrust Banks upped their price target on shares of Teladoc to $100.00 and gave the stock a “buy” rating in a research report on Monday. Piper Jaffray Companies upped their price target on shares of Teladoc to $84.00 and gave the stock an “overweight” rating in a research report on Friday, September 21st. Citigroup upped their price target on shares of Teladoc from $80.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, September 21st. Canaccord Genuity upped their price target on shares of Teladoc from $70.00 to $86.00 and gave the stock a “buy” rating in a research report on Thursday, September 20th. Finally, KeyCorp upped their price target on shares of Teladoc from $74.00 to $90.00 and gave the stock an “overweight” rating in a research report on Monday, August 27th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $67.80.
Teladoc stock opened at $78.55 on Thursday. Teladoc has a 52-week low of $27.30 and a 52-week high of $82.40. The firm has a market capitalization of $5.46 billion, a PE ratio of -47.61 and a beta of 0.58. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.58.
Teladoc (NYSE:TDOC) last released its quarterly earnings data on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.01. Teladoc had a negative net margin of 37.78% and a negative return on equity of 19.10%. The company had revenue of $94.60 million during the quarter, compared to analyst estimates of $91.56 million. During the same quarter in the prior year, the business earned ($0.28) earnings per share. The business’s quarterly revenue was up 112.1% compared to the same quarter last year. research analysts anticipate that Teladoc will post -1.51 EPS for the current fiscal year.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Recommended Story: What is a Stop Order?
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.